Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90006 in mild to moderate plaque-type psoriasis
NCT03337022Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2018
- Primary completion
- Apr 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of CC-90006 in plaque psoriasis (5 arms), sponsored by Celgene Corporation. Primary endpoint: Adverse Events (AEs). Started Jan 2018; status: completed.
02
Drugs
CC-90006
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03337022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337022.